CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 61,300 shares, a decrease of 6.6% from the December 15th total of 65,600 shares. Based on an average daily trading volume, of 59,400 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.9% of the company’s shares are sold short.

CalciMedica Trading Down 2.5 %

Shares of CALC traded down $0.08 during trading hours on Monday, reaching $3.09. The company had a trading volume of 21,907 shares, compared to its average volume of 25,828. The company has a market capitalization of $41.65 million, a price-to-earnings ratio of -2.86 and a beta of 1.22. The firm has a 50 day simple moving average of $3.13 and a 200-day simple moving average of $3.86. CalciMedica has a 12-month low of $2.05 and a 12-month high of $8.38.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $325,751.25. Following the completion of the purchase, the insider now owns 814,300 shares in the company, valued at $3,053,625. This trade represents a 11.94 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Eric W. Roberts bought 53,333 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average price of $3.75 per share, with a total value of $199,998.75. Following the purchase, the insider now directly owns 164,706 shares of the company’s stock, valued at approximately $617,647.50. This trade represents a 47.89 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 252,744 shares of company stock valued at $942,510 over the last 90 days. 41.55% of the stock is owned by insiders.

Institutional Investors Weigh In On CalciMedica

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after purchasing an additional 22,525 shares in the last quarter. Atria Investments Inc boosted its stake in shares of CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new stake in shares of CalciMedica during the third quarter worth approximately $67,000.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research note on Thursday, November 14th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.